COMMUNIQUÉS West-GlobeNewswire

Cloudcure Launches Companion App to Close Clinical Adherence Gap in Metabolic Health
09/03/2026
Toronto, ON, March 09, 2026 (GLOBE NEWSWIRE) -- Cloudcure, a specialized health platform dedicated to improving metabolic health through evidence-based, personalized medicine, has announced the launch of its new weight [...]
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
09/03/2026
Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucel Smital Shah appointed Chief Financial and Business Officer SOUTH [...]
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company [...]
SRx Health Solutions Launches EventHorizonIQ Subscription for Individual and Institutional Traders
09/03/2026
EventHorizonIQ, available now at https://eventhorizoniq.com/pricing , provides investors and risk professionals with institutional-grade cross-asset regime intelligence Subscription launch represents first proprietary [...]
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
09/03/2026
-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with [...]
BeautyHealth Expands Skin Health Ecosystem with Growing Adoption of SkinStylus Nano-Channeling, a Popular Pairing with Hydrafacial Treatments
09/03/2026
The Hydrafacial Treatment and SkinStylus Nano-Channeling Protocol Addresses Rising Consumer Demand for Combination Treatments That Can Improve Performance and Enhance Results LONG BEACH, Calif., March 09, 2026 (GLOBE [...]
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
09/03/2026
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • [...]
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
09/03/2026
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
09/03/2026
RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
09/03/2026
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to [...]
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
09/03/2026
Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will participate in the [...]
NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH
09/03/2026
--- Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration Key Highlights: Monotherapy and Clinical Outcomes The 12-16-week open-label [...]
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
09/03/2026
– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and [...]
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and [...]
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
09/03/2026
Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those stable with an enzyme [...]
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
09/03/2026
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late- [...]
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
09/03/2026
TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
09/03/2026
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK ), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially [...]
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
09/03/2026
HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conference Data showing narmafotinib activity in preclinical models of pancreatic [...]

Pages